Ming, Professor of the Department of Chemical and Biological Engineering (CBE) at The Hong Kong University of Science and ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

We'll know more about the company's medium-term prospects by the end of the year.

In this GEN webinar, Tilmann Buerckstuemmer, PhD, CSO at Myllia Biotechnology will show how high-throughput pooled CRISPR ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

CRISPR-Cas9 is an RNA-guided DNA-cutting enzyme system that allows researchers to modify the genetic code of virtually any organism with a precision, speed, and affordability previously unattainable.

Biotech innovation has hit three notable milestones: Bambusa Therapeutics completed enrolment for its first atopic dermatitis drug trial, a one-patient gene-editing therapy corrected a fatal CPS1 ...